Posterıor reversıble leukoencephalopathy syndrome developıng secondary tosunıtınıb therapy ın a patıent wıth metastatıc renal cell carcınoma

Basit Öğe Kaydı
dc.contributor.authorKaplan, Nihal Bozdag
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorDikilitas, Mustafa
dc.contributor.authorElkiran, Emin Tamer
dc.contributor.authorTemelli, Oztun
dc.date.accessioned2019-07-17T12:19:46Z
dc.date.available2019-07-17T12:19:46Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPosterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema occurring generally in parietal and occipital areas of the brain as a result of different etiologic causes and it is diagnosed by means of clinical and radiologic assessment. Sunitinib is an orally administered tyrosine kinase inhibitor used in the treatment of renal cell carcinoma with its antiangiogenic and antitumor effects. Fatigue, nausea-vomiting, diarrhea, hypertension, cardiotoxicity, hypothyroidism, neutropenia, and skin toxicity are among common side effects associated with sunitinib therapy. The current report presents a female patient with metastatic papillary renal cell cancer who developed posterior reversible encephalopathy syndrome as determined by means of clinical and radiologic assessment at 8 months of sunitinib therapy and who completely recovered with antihypertensive, antiepileptic, and antiedema therapy.en_US
dc.identifier.citationKaplan, NB. Harputluoglu, H. Dikilitas, M. Elkiran, ET. Temelli, O. (2018). Posterıor reversıble leukoencephalopathy syndrome developıng secondary tosunıtınıb therapy ın a patıent wıth metastatıc renal cell carcınoma. Cilt:34. Sayı:1. 39-42 ss.en_US
dc.identifier.doi10.19193/0393-6384_2018_1_6en_US
dc.identifier.endpage42en_US
dc.identifier.issue1en_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://hdl.handle.net/11616/12687
dc.identifier.volume34en_US
dc.language.isoenen_US
dc.publisherCarbone edıtore, vıa quıntıno sella, 68, palermo, 90139, ıtalyen_US
dc.relation.ispartofActa medıca medıterraneaen_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectCanceren_US
dc.titlePosterıor reversıble leukoencephalopathy syndrome developıng secondary tosunıtınıb therapy ın a patıent wıth metastatıc renal cell carcınomaen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Koleksiyonu